MEDVi vs Ro: Which GLP-1 Provider Is Better?
By Iacob Pastina, Independent Researcher
MEDVi beats Ro overall, scoring 7.7/10 vs 7.2/10. MEDVi is more affordable at $299/mo vs $344/mo. Choose MEDVi for users who want a low entry price with oral and injectable co. Choose Ro for users with insurance who want brand-name medications from a .
A side-by-side comparison of MEDVi and Ro covering pricing, scores, medication types, insurance, and more to help you decide.
MEDVi
#21 of 40Compounded GLP-1 platform offering both oral and injectable options with flexible dosing and affordable pricing.
Visit MEDViRo
#36 of 40One of the most recognized telehealth brands offering brand-name GLP-1 medications with insurance support and a streamlined process.
Visit Ro| Feature | MEDVi | Ro |
|---|---|---|
| Our Score | 7.7/10 | 7.2/10 |
| Starting Price | $299/mo | $344/mo |
| Medication Type | Compounded | Brand |
| Insurance Accepted | No | Yes |
| Best For | Users who want a low entry price with oral and injectable compounded options | Users with insurance who want brand-name medications from a trusted platform |
| Ranking | #21 | #36 |
Pros & Cons Compared
MEDVi
Pros
- +One of the few compounded providers offering both oral tablets and injectable semaglutide
- +Micro-dosing options available — can start at sub-standard doses for patients concerned about side effects
- +Sleek onboarding experience with clear progress tracking through their patient portal
- +$179/mo is competitive for a platform with both oral and injectable compounded formulations
Cons
- −Compounded medications only — no path to brand-name Wegovy or Zepbound through their platform
- −No insurance accepted, and oral compounded semaglutide has less clinical data than injectable forms
Ro
Pros
- +The most recognized telehealth brand in GLP-1s — operating since 2017 with millions of patients served
- +Direct insurance billing with major carriers — with coverage, Wegovy or Zepbound can cost $0-25/mo copay
- +$99/mo self-pay starting price for brand-name medications, among the lowest for FDA-approved drugs
- +Same-day prescriptions common — streamlined intake means most patients get approved within hours
Cons
- −Brand-name only — no compounded semaglutide or tirzepatide, which means no cheaper generic alternatives
- −Without insurance, brand-name costs jump significantly ($299+/mo for Wegovy at higher doses)
Our Verdict
MEDVi edges out Ro with a score of 7.7/10 vs 7.2/10. If budget is your priority, MEDVi starts at $299/mo compared to Ro's $344/mo. Ro accepts insurance, which can significantly reduce your out-of-pocket costs. Choose MEDVi if you want: users who want a low entry price with oral and injectable compounded options. Choose Ro if you want: users with insurance who want brand-name medications from a trusted platform.